CHF81.60
0.49%
SIX Swiss Exchange, Oct 02, 09:47 am CEST. Market open.
ISIN
CH0386200239
Symbol
MED

Medartis Target price 2026 - Analyst rating & recommendation

Medartis Classifications & Recommendation

Buy
86%
Hold
14%

Medartis Price Target

Target Price CHF106.59
Price CHF82.00
Potential
Number of Estimates 3
3 Analysts have issued a price target Medartis 2027 . The average Medartis target price is CHF106.59. This is higher than the current stock price. The highest price target is
CHF110.25 34.45%
register free of charge
, the lowest is
CHF105.04 28.10%
register free of charge
.
A rating was issued by 7 analysts: 6 Analysts recommend Medartis to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medartis stock has an average upside potential 2027 of . Most analysts recommend the Medartis stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million CHF 269.26 337.34
19.76% 25.28%
EBITDA Margin 16.55% 18.25%
12.31% 10.30%
Net Margin 3.10% 5.38%
97.51% 73.49%

4 Analysts have issued a sales forecast Medartis 2026 . The average Medartis sales estimate is

CHF337m
unlock
. This is
9.86% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF356m 16.03%
unlock
, the lowest is
CHF319m 3.73%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 CHF269m 19.76%
2026
CHF337m 25.28%
unlock
2027
CHF393m 16.39%
unlock
2028
CHF454m 15.70%
unlock
2029
CHF395m 13.07%
unlock
2030
CHF423m 7.10%
unlock
2031
CHF451m 6.61%
unlock
2032
CHF479m 6.22%
unlock

4 Analysts have issued an Medartis EBITDA forecast 2026. The average Medartis EBITDA estimate is

CHF61.6m
unlock
. This is
0.01% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF65.1m 5.76%
unlock
, the lowest is
CHF58.6m 4.87%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 CHF44.6m 5.02%
2026
CHF61.6m 38.17%
unlock
2027
CHF76.7m 24.60%
unlock
2028
CHF95.2m 24.13%
unlock

EBITDA Margin

2025 16.55% 12.31%
2026
18.25% 10.30%
unlock
2027
19.53% 7.01%
unlock
2028
20.96% 7.32%
unlock

4 Medartis Analysts have issued a net profit forecast 2026. The average Medartis net profit estimate is

CHF18.2m
unlock
. This is
21.72% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF19.8m 32.57%
unlock
, the lowest is
CHF16.4m 9.58%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 CHF8.4m 136.54%
2026
CHF18.2m 117.49%
unlock
2027
CHF28.3m 55.95%
unlock
2028
CHF41.3m 45.83%
unlock

Net Margin

2025 3.10% 97.51%
2026
5.38% 73.49%
unlock
2027
7.21% 34.01%
unlock
2028
9.09% 26.07%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share CHF 0.67 1.46
131.03% 117.91%
P/E 56.21
EV/Sales 4.00

4 Analysts have issued a Medartis forecast for earnings per share. The average Medartis EPS is

CHF1.46
unlock
. This is
23.73% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
CHF1.59 34.75%
unlock
, the lowest is
CHF1.31 11.02%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 CHF0.67 131.03%
2026
CHF1.46 117.91%
unlock
2027
CHF2.27 55.48%
unlock
2028
CHF3.32 46.26%
unlock

P/E ratio

Current 69.49 102.44%
2026
56.21 19.11%
unlock
2027
36.05 35.87%
unlock
2028
24.72 31.43%
unlock

Based on analysts' sales estimates for 2026, the Medartis stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.39 10.77%
2026
4.00 8.97%
unlock
2027
3.43 14.08%
unlock
2028
2.97 13.57%
unlock
2029
3.41 15.03%
unlock
2030
3.19 6.63%
unlock
2031
2.99 6.20%
unlock
2032
2.81 5.86%
unlock

P/S ratio

Current 3.73 23.42%
2026
3.40 8.98%
unlock
2027
2.92 14.08%
unlock
2028
2.52 13.57%
unlock
2029
2.90 15.03%
unlock
2030
2.71 6.63%
unlock
2031
2.54 6.20%
unlock
2032
2.39 5.85%
unlock

Current Medartis Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
STIFEL EUROPE
Locked
➜
Locked
Locked Sep 17 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jun 26 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jun 25 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jan 19 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jan 18 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Aug 19 2025
STIFEL EUROPE
Locked
➜
Locked
Locked Jul 17 2025
Analyst Rating Date
Locked
STIFEL EUROPE:
Locked
➜
Locked
Sep 17 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jun 26 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jun 25 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jan 19 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jan 18 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Aug 19 2025
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jul 17 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today